Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase NA 6Phase 1/2 5Phase 1 5Phase 3 2Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 2Recurrence 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Lymphoid 1Leukemia 1Hematologic Neoplasms 1

Interventions

fludarabine phosphate 1fludarabine 1Thiotepa 1Sirolimus 1Radiotherapy 1Prednisone 1Influenza Vaccines 1Fluzone High-Dose 1Filgrastim 1Everolimus 1Cyclophosphamide 1Busulfan 1Antilymphocyte Serum 113-valent pneumococcal vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms, Plasma Cell × Busulfan × Clear all
NCT00361140 2017-03-03

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

H. Lee Moffitt Cancer Center and Research Institute

Phase 4 Completed
72 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoid, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡